<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01915901</url>
  </required_header>
  <id_info>
    <org_study_id>109HV110</org_study_id>
    <nct_id>NCT01915901</nct_id>
  </id_info>
  <brief_title>PeptoBismol® Use to Reduce Gastrointestinal Events in Healthy Volunteers Receiving DMF [Tecfidera®] Twice Daily</brief_title>
  <official_title>A Multicenter, Double Blind, Placebo-Controlled Study of Pepto-Bismol® (Bismuth Subsalicylate) on Gastrointestinal Tolerability in Healthy Volunteers Receiving Oral TECFIDERA™ (Dimethyl Fumarate) Delayed-Release Capsules Twice Daily</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <brief_summary>
    <textblock>
      The primary objective of the study is to determine the effect of bismuth subsalicylate&#xD;
      (Pepto-Bismol®) 524 mg versus placebo on gastrointestinal (GI)-related events reported in&#xD;
      healthy volunteers receiving TECFIDERA™ (dimethyl fumarate [DMF]; also known as BG00012)&#xD;
      twice daily (BID) The secondary objectives of this study in this study population are: To&#xD;
      characterize the effect of bismuth subsalicylate (Pepto-Bismol®) 524 mg versus placebo on the&#xD;
      frequency, severity, and duration of GI-related events and to evaluate GI-related events that&#xD;
      lead to discontinuation of DMF.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to first gastrointestinal-related event</measure>
    <time_frame>Up to 8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of gastrointestinal-related events.</measure>
    <time_frame>Up to 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The duration of gastrointestinal-related events.</measure>
    <time_frame>Up to 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The severity of gastrointestinal-related events.</measure>
    <time_frame>Up to 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects who discontinue dimethyl fumarate (DMF) due to gastrointestinal-related events</measure>
    <time_frame>Up to 8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">175</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>bismuth subsalicylate (Pepto-Bismol®) + DMF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive dimethyl fumarate (DMF) and bismuth subsalicylate (Pepto-Bismol®).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + DMF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive dimethyl fumarate (DMF) and placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bismuth subsalicylate (Pepto-Bismol®)</intervention_name>
    <description>524 mg bismuth subsalicylate twice a day (BID)</description>
    <arm_group_label>bismuth subsalicylate (Pepto-Bismol®) + DMF</arm_group_label>
    <other_name>Pepto-Bismol®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>matching placebo (bismuth subsalicylate)</intervention_name>
    <description>placebo twice a day (BID)</description>
    <arm_group_label>Placebo + DMF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dimethyl fumarate (DMF)</intervention_name>
    <description>dimethyl fumarate (DMF) twice a day (BID)</description>
    <arm_group_label>Placebo + DMF</arm_group_label>
    <arm_group_label>bismuth subsalicylate (Pepto-Bismol®) + DMF</arm_group_label>
    <other_name>BG00012</other_name>
    <other_name>DMF</other_name>
    <other_name>TECFIDERA™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Must be in good health as determined by the Principal Investigator (PI) based on&#xD;
             medical history and Screening evaluations (clinical laboratory evaluations, 12-lead&#xD;
             electrocardiogram (ECG), and vital signs; see below for specific exclusion criteria).&#xD;
&#xD;
          -  Must have a body mass index (BMI) of 18.0 to 34.0 kg/m2, inclusive.&#xD;
&#xD;
          -  Subjects of reproductive potential (including males) must practice effective&#xD;
             contraception during the study and be willing and able to continue contraception for&#xD;
             90 days after their last dose of study drug.&#xD;
&#xD;
          -  Male subjects must agree to not donate sperm for 90 days after their last dose of&#xD;
             study drug.&#xD;
&#xD;
          -  Must be naïve to dimethyl fumarate (DMF) or fumaric acid esters.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  History of or positive results at the Screening visit for HIV.&#xD;
&#xD;
          -  History of or positive results at the Screening visit for hepatitis C virus antibody&#xD;
             or hepatitis B virus (defined as positive for hepatitis B surface antigen [HBsAg] or&#xD;
             hepatitis B core antibody [HBcAb]).&#xD;
&#xD;
          -  History of clinically significant gastrointestinal (GI) disease as determined by the&#xD;
             PI (including Crohn's disease, peptic ulcer disease, ulcerative colitis, or confirmed&#xD;
             diagnosis of irritable bowel syndrome) or active GI disease with ongoing symptoms.&#xD;
&#xD;
          -  History of severe allergic or anaphylactic reactions, considered clinically relevant&#xD;
             by the PI.&#xD;
&#xD;
          -  Known allergy to Pepto-Bismol®, salicylates, or non-steroidal anti-inflammatory drugs,&#xD;
             considered clinically relevant by the PI.&#xD;
&#xD;
          -  Female subjects who are pregnant based on results of the serum pregnancy test at&#xD;
             Screening or currently breastfeeding.&#xD;
&#xD;
          -  Current enrollment in any other study treatment or disease study.&#xD;
&#xD;
          -  Receipt of any investigational drug within 5 half-lives or 30 days, whichever is&#xD;
             longer, prior to study entry.&#xD;
&#xD;
          -  History of alcohol abuse or substance abuse (as determined by the PI) within the&#xD;
             previous 5 years, a positive urine drug/alcohol test at Screening, or alcohol use&#xD;
             prior to the screening visit.&#xD;
&#xD;
          -  Regular use of any tobacco product, defined as smoke or smokeless product use&#xD;
             equivalent to &gt;5 cigarettes/day for any consecutive week, within 3 months prior to Day&#xD;
             1.&#xD;
&#xD;
        Other unspecified reasons that, in the opinion of the PI or Biogen Idec, make the subject&#xD;
        unsuitable for enrollment.&#xD;
&#xD;
        Other protocol-defined Inclusion/Exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>August 1, 2013</study_first_submitted>
  <study_first_submitted_qc>August 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2013</study_first_posted>
  <last_update_submitted>February 28, 2014</last_update_submitted>
  <last_update_submitted_qc>February 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dimethyl Fumarate</mesh_term>
    <mesh_term>Bismuth</mesh_term>
    <mesh_term>Bismuth subsalicylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

